Current Radiopharmaceuticals
Title:Meet Our Editorial Board Member
Volume: 10 Issue: 1
Author(s): Peter J. H. Scott
Affiliation:
Export Options
About this article
Cite this article as:
Scott J. H. Peter, Meet Our Editorial Board Member, Current Radiopharmaceuticals 2017; 10 (1) . https://dx.doi.org/10.2174/187447101001170308175951
DOI https://dx.doi.org/10.2174/187447101001170308175951 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
15
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Overview on Global Trends in Nanotechnological Approaches for Alzheimer Therapy
Current Drug Metabolism A Synopsis on the Role of Tyrosine Hydroxylase in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Conference Report: 10th Clinical Trials on Alzheimer's Disease (CTAD), Boston MA, USA, November 1-4, 2017
CNS & Neurological Disorders - Drug Targets Mechanisms of Tau Self-Aggregation and Neurotoxicity
Current Alzheimer Research Recent Patents Review on Intranasal Administration for CNS Drug Delivery
Recent Patents on Drug Delivery & Formulation PP2A and Alzheimer Disease
Current Alzheimer Research Neuronal Death in Amyotrophic Lateral Sclerosis (ALS): What Can We Learn from Genetics?
CNS & Neurological Disorders - Drug Targets Transgenic Mouse Models of Alzheimer Disease: Developing a Better Model as a Tool for Therapeutic Interventions
Current Pharmaceutical Design Inhibitors of Cyclin-Dependent Kinases: Potential Drugs for the Treatment of Neurodegenerative Disorders?
Current Medicinal Chemistry - Central Nervous System Agents Growth Hormone and Insulin-Like Growth Factor-I as an Endocrine Axis in Alzheimers Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Raf Inhibitors as Therapeutic Agents Against Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Protein Aggregation in Neurodegenerative Diseases: Insights from Computational Analyses
Current Bioinformatics Current Advances on Different Kinases Involved in Tau Phosphorylation, and Implications in Alzheimers Disease and Tauopathies
Current Alzheimer Research Molecular Targets of Tannic Acid in Alzheimer's Disease
Current Alzheimer Research Transglutaminase-Catalyzed Reactions Responsible for the Pathogenesis ofCeliac Disease and Neurodegenerative Diseases: From Basic Biochemistry to Clinic
Current Medicinal Chemistry Recent Advances in Treatment Approaches to Gaucher Disease
Current Pharmaceutical Biotechnology Tau as a Molecular Marker of Development, Aging and Neurodegenerative Disorders
Current Aging Science Editorial [Hot topic: Tau, Neurodegeneration and Alzheimers Disease (Guest Editor: Alejandra del Carmen Alonso)]
Current Alzheimer Research Real-world Utilisation of the Rivastigmine Transdermal Patches Accompanying the Use of Risk Minimisation Tools in Patients with Dementia
Current Alzheimer Research 11C-verapamil to Assess P-gp Function in Human Brain During Aging,Depression and Neurodegenerative Disease
Current Topics in Medicinal Chemistry